A Monoclonal Antibody Against a Potential Cancer Biomarker, Human Ubiquitin-conjugating Enzyme E2

Overview

Journal Hybridoma (Larchmt)

Date 2012 Jun 30

PMID 22741584

Citations 4

Authors

Hongyan Du

Ligang Jie

Weiwen Xu

Yingsong Wu

Tiancai Liu

Ming Li

Affiliations

Soon will be listed here.

Abstract

Human ubiquitin-conjugating enzyme E2, also known as UbcH10, is defined as a cyclin-selective ubiquitin carrier protein and is essential for selective degradation of many short-lived proteins in eukaryotic cells. Recently more and more data show that UbcH10 could be a potential cancer biomarker. In this study, we have developed a monoclonal antibody (MAb) against UbcH10 using an expression recombinant protein. Hybridomas F001, F007, and F008 with high affinities belong to IgG1 subclass with κ light and are highly specific for UbcH10. Further experimentation showed that MAbs F001, F007, and F008 are suitable for the development of immunoassay core agents with sufficient sensitivity and specificity in vitro by Western-blot, immunofluorescence, and immunohistochemistry. These MAbs can be used as a tool for further investigation on functions related to the role of UbcH10 in tumorigenesis and development.

Citing Articles

Circadian clock protein CRY1 prevents paclitaxel‑induced senescence of bladder cancer cells by promoting p53 degradation.

Jia M, Su B, Mo L, Qiu W, Ying J, Lin P Oncol Rep. 2021; 45(3):1033-1043.

PMID: 33650658 PMC: 7860017. DOI: 10.3892/or.2020.7914.

Cancer Cell enters reversible quiescence through Intracellular Acidification to resist Paclitaxel Cytotoxicity.

Jia M, Zheng D, Wang X, Zhang Y, Chen S, Cai X Int J Med Sci. 2020; 17(11):1652-1664.

PMID: 32669967 PMC: 7359388. DOI: 10.7150/ijms.46034.

UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines.

Palumbo Jr A, Meireles Da Costa N, De Martino M, Sepe R, Pellecchia S, de Sousa V Oncotarget. 2016; 7(40):65876-65887.

PMID: 27588470 PMC: 5323199. DOI: 10.18632/oncotarget.11674.

Comparative proteomics analysis of oral cancer cell lines: identification of cancer associated proteins.

Karsani S, Saihen N, Zain R, Cheong S, Abdul Rahman M Proteome Sci. 2014; 12(1):3.

PMID: 24422745 PMC: 3974152. DOI: 10.1186/1477-5956-12-3.

References

Walker G, Macleod K, Williams A, Cameron D, Smyth J, Langdon S . Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol. 2007; 106(3):461-8. DOI: 10.1016/j.ygyno.2007.05.009. View

Ganoth D, Leshinsky E, Eytan E, Hershko A . A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation. J Biol Chem. 1988; 263(25):12412-9. View

Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K . Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007; 121(1):33-8. DOI: 10.1002/ijc.22605. View

Troncone G, Guerriero E, Pallante P, Pallante P, Berlingieri M, Ferraro A . UbcH10 expression in human lymphomas. Histopathology. 2009; 54(6):731-40. DOI: 10.1111/j.1365-2559.2009.03296.x. View

Pallante P, Berlingieri M, Troncone G, Kruhoffer M, Orntoft T, Viglietto G . UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer. 2005; 93(4):464-71. PMC: 2361574. DOI: 10.1038/sj.bjc.6602721. View

Fujita T, Ikeda H, Taira N, Hatoh S, Naito M, Doihara H . Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer. 2009; 9:87. PMC: 2666760. DOI: 10.1186/1471-2407-9-87. View

Rosen S, Winter J, Epstein A . Application of monoclonal antibodies to tumor diagnosis and therapy. Ann Clin Lab Sci. 1983; 13(3):173-84. View

Berlingieri M, Pallante P, Sboner A, Barbareschi M, Bianco M, Ferraro A . UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer. 2007; 43(18):2729-35. DOI: 10.1016/j.ejca.2007.09.003. View

van Ree J, Jeganathan K, Malureanu L, van Deursen J . Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol. 2010; 188(1):83-100. PMC: 2812857. DOI: 10.1083/jcb.200906147. View

10.

Shi D, Grossman S . Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol Ther. 2010; 10(8):737-47. PMC: 3023568. DOI: 10.4161/cbt.10.8.13417. View

11.

Wagner K, Sapinoso L, El-Rifai W, Frierson H, Butz N, Mestan J . Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 2004; 23(39):6621-9. DOI: 10.1038/sj.onc.1207861. View

12.

Jiang L, Bao Y, Luo C, Hu G, Huang C, Ding X . Knockdown of ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro. J Cancer Res Clin Oncol. 2009; 136(2):211-7. DOI: 10.1007/s00432-009-0651-z. View

13.

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A . UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003; 63(14):4167-73. View

14.

Lin Y, Hwang W, Basavappa R . Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10. J Biol Chem. 2002; 277(24):21913-21. DOI: 10.1074/jbc.M109398200. View

15.

Chen S, Jiang C, Wu J, Liu B, Chen Y, Hu C . RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo. Clin Exp Pharmacol Physiol. 2010; 37(5-6):525-9. DOI: 10.1111/j.1440-1681.2009.05348.x. View

16.

Chen S, Chen Y, Hu C, Jing H, Cao Y, Liu X . Association of clinicopathological features with UbcH10 expression in colorectal cancer. J Cancer Res Clin Oncol. 2009; 136(3):419-26. DOI: 10.1007/s00432-009-0672-7. View

17.

Israeli O, Goldring-Aviram A, Rienstein S, Ben-Baruch G, Korach J, Goldman B . In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet. 2005; 160(1):35-42. DOI: 10.1016/j.cancergencyto.2004.11.011. View

18.

Berlingieri M, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G . UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 2006; 26(14):2136-40. DOI: 10.1038/sj.onc.1210010. View

19.

Townsley F, Aristarkhov A, Beck S, Hershko A, Ruderman J . Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci U S A. 1997; 94(6):2362-7. PMC: 20093. DOI: 10.1073/pnas.94.6.2362. View

20.

Lin J, Raoof D, Wang Z, Lin M, Thomas D, Greenson J . Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia. 2007; 8(12):1062-71. PMC: 1783715. DOI: 10.1593/neo.05832. View